Ranger紫杉醇涂层球囊治疗股腘动脉病变的6个月随机研究结果
RANGER SFA研究在10个欧洲中心随机纳入105例有症状的下肢缺血患者,比较Ranger紫杉醇涂层球囊与无涂层球囊血管成形术治疗股腘动脉病变的效果。6个月时DCB组晚期管腔丢失显著低于对照组,免于二元再狭窄率和一期通畅率显著更高,两组靶病变血运重建率无显著差异,无截肢或器械相关死亡。
要点
- Ranger DCB组6个月晚期管腔丢失显著优于对照组(-0.16±0.99 vs 0.76±1.4,p=0.002)。
- DCB组免于二元再狭窄率92% vs 64%(p=0.005),一期通畅率87% vs 60%(p=0.014)。
- 两组靶病变血运重建率5.6% vs 12%(p=0.475),无截肢或器械相关死亡。
核心结论
- Ranger DCB治疗有症状股腘动脉病变在6个月时有效抑制再狭窄,改善血管通畅性且血运重建率低。
研究设计与样本
- 前瞻性随机RANGER SFA研究(NCT02013193),2014年1月至2015年10月纳入10个欧洲中心105例有症状下肢缺血(Rutherford 2-4级)患者。
- 6个月分析包括血管造影晚期管腔丢失及安全性和临床结局评估。
主要发现
- 两组基线特征相似,病变长度68±46 vs 60±48 mm(p=0.731),钙化严重程度(p=0.236),闭塞比例34% vs 34%(p>0.999)。
- 6个月晚期管腔丢失DCB组显著低于对照组(-0.16±0.99 vs 0.76±1.4,p=0.002)。
- DCB组免于二元再狭窄率显著更高(92% vs 64%,p=0.005)。
- DCB组一期通畅率显著更高(87% vs 60%,p=0.014)。
- 靶病变血运重建率DCB组5.6%,对照组12%(p=0.475);两组均无靶肢体截肢或器械相关死亡。
临床怎么用
- 对于有症状的股腘动脉非支架段狭窄病变,Ranger DCB可作为改善6个月通畅性的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the performance of the Ranger paclitaxel-coated balloon vs uncoated balloon angioplasty for femoropopliteal lesions. METHODS: Between January 2014 and October 2015, the prospective, randomized RANGER SFA study ( ClinicalTrials.gov identifier NCT02013193) enrolled 105 patients with symptomatic lower limb ischemia (Rutherford category 2-4) and stenotic lesions in the nonstented femoropopliteal segment at 10 European centers. Seventy-one patients (mean age 68±8 years; 53 men) were enrolled in the Ranger drug-coated balloon (DCB) arm and 34 patients (mean age 67±9 years; 23 men) were assigned to the control group. Six-month analysis included angiographic late lumen loss and safety and clinical outcomes assessments. RESULTS: Baseline characteristics of the DCB and control groups were similar, as were lesion lengths (68±46 vs 60±48 mm; p=0.731), severity of calcification (p=0.236), and the prevalence of occlusions (34% vs 34%; p>0.999). At 6 months, late lumen loss was significantly less for the DCB group vs controls (-0.16±0.99 vs 0.76±1.4; p=0.002). The DCB group had significantly greater freedom from binary restenosis (92% vs 64%; p=0.005) and primary patency rates (87% vs 60%; p=0.014). Target lesion revascularization rates were 5.6% in the DCB group and 12% in the control group (p=0.475). No target limb amputations or device-related deaths occurred in either group. CONCLUSION: Six-month results suggest that Ranger DCB treatment effectively inhibited restenosis in symptomatic femoropopliteal disease, resulting in improved vessel patency and a low revascularization rate in the short term compared with uncoated balloon angioplasty.
引用
- Bausback Y, Willfort-Ehringer A, Sievert H, et al. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment. J Endovasc Ther. 2017. PMID: 28558502. doi:10.1177/1526602817710770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。